全文获取类型
收费全文 | 1080篇 |
免费 | 166篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 69篇 |
妇产科学 | 12篇 |
基础医学 | 269篇 |
口腔科学 | 19篇 |
临床医学 | 177篇 |
内科学 | 243篇 |
皮肤病学 | 14篇 |
神经病学 | 39篇 |
特种医学 | 178篇 |
外科学 | 88篇 |
综合类 | 14篇 |
预防医学 | 44篇 |
眼科学 | 8篇 |
药学 | 73篇 |
肿瘤学 | 23篇 |
出版年
2021年 | 22篇 |
2020年 | 9篇 |
2019年 | 13篇 |
2018年 | 19篇 |
2017年 | 10篇 |
2016年 | 12篇 |
2015年 | 15篇 |
2014年 | 29篇 |
2013年 | 38篇 |
2012年 | 40篇 |
2011年 | 28篇 |
2010年 | 20篇 |
2009年 | 21篇 |
2008年 | 19篇 |
2007年 | 37篇 |
2006年 | 36篇 |
2005年 | 27篇 |
2004年 | 30篇 |
2003年 | 29篇 |
2002年 | 33篇 |
2001年 | 25篇 |
2000年 | 21篇 |
1999年 | 25篇 |
1998年 | 37篇 |
1997年 | 32篇 |
1996年 | 44篇 |
1995年 | 30篇 |
1994年 | 27篇 |
1993年 | 30篇 |
1992年 | 25篇 |
1991年 | 15篇 |
1990年 | 27篇 |
1989年 | 29篇 |
1988年 | 32篇 |
1987年 | 38篇 |
1986年 | 18篇 |
1985年 | 34篇 |
1984年 | 23篇 |
1983年 | 17篇 |
1982年 | 25篇 |
1981年 | 16篇 |
1980年 | 16篇 |
1979年 | 13篇 |
1978年 | 12篇 |
1977年 | 23篇 |
1976年 | 27篇 |
1975年 | 26篇 |
1973年 | 13篇 |
1972年 | 14篇 |
1970年 | 11篇 |
排序方式: 共有1271条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
L. J. Anderson W. Henley K. M. Wyatt V. Nikolaou S. Waldek D. A. Hughes R. H. Lachmann S. Logan 《Journal of inherited metabolic disease》2014,37(6):945-952
Objectives
To determine the effectiveness of enzyme replacement therapy (ERT) for adults with late-onset Pompe disease.Design
A longitudinal cohort study including prospective and retrospective clinical outcome data. Age- and gender-adjusted treatment effects were estimated using generalised linear mixed models. Treated patients contributed data before and during treatment. Untreated patients contributed natural history data.Participants
Consenting adults (N?=?62) with a diagnosis of late-onset Pompe disease who attended a specialist treatment centre in England. This cohort represented 83 % of all patients in the UK with a confirmed diagnosis of this rare condition. At study entry, all but three patients were receiving ERT (range of treatment duration, 0 to 3.1 years).Outcome measures
Percent predicted forced vital capacity (%FVC); ventilation dependency; mobility; 6 min walk test (6MWT); muscle strength and body mass index (BMI).Results
An association was found between time on ERT and significant increases in the distance walked in the 6MWT (p?0.001) and muscle strength scores (p?0.001). Improvements in both these measures were seen over the first 2 years of treatment with ERT. No statistically significant relationship was found between time on ERT and respiratory function or in BMI.Conclusions
These data provide some further evidence of the effectiveness of ERT in adults with late-onset Pompe disease.Synopsis
The results of this longitudinal cohort study of 62 adults with late-onset Pompe disease, provide further evidence on the effectiveness of ERT in this rare condition. 相似文献55.
56.
Youssif Mohammed Ali Azam Hayat Bayad Mawlood Saeed Kashif S. Haleem Saleh Alshamrani Hany I. Kenawy Viviana P. Ferreira Gurpanna Saggu Anna Buchberger Peter J. Lachmann Robert B. Sim Dimitrios Goundis Peter W. Andrew Nicholas J. Lynch Wilhelm J. Schwaeble 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(14):5301-5306
Modern medicine has established three central antimicrobial therapeutic concepts: vaccination, antibiotics, and, recently, the use of active immunotherapy to enhance the immune response toward specific pathogens. The efficacy of vaccination and antibiotics is limited by the emergence of new pathogen strains and the increased incidence of antibiotic resistance. To date, immunotherapy development has focused mainly on cytokines. Here we report the successful therapeutic application of a complement component, a recombinant form of properdin (Pn), with significantly higher activity than native properdin, which promotes complement activation via the alternative pathway, affording protection against N. menigitidis and S. pneumoniae. In a mouse model of infection, we challenged C57BL/6 WT mice with N. menigitidis B-MC58 6 h after i.p. administration of Pn (100 µg/mouse) or buffer alone. Twelve hours later, all control mice showed clear symptoms of infectious disease while the Pn treated group looked healthy. After 16 hours, all control mice developed sepsis and had to be culled, while only 10% of Pn treated mice presented with sepsis and recoverable levels of live Meningococci. In a parallel experiment, mice were challenged intranasally with a lethal dose of S. pneumoniae D39. Mice that received a single i.p. dose of Pn at the time of infection showed no signs of bacteremia at 12 h postinfection and had prolonged survival times compared with the saline-treated control group (P < 0.0001). Our findings show a significant therapeutic benefit of Pn administration and suggest that its antimicrobial activity could open new avenues for fighting infections caused by multidrug-resistant neisserial or streptococcal strains.Pneumococcal and meningococcal infectious diseases remain a serious threat to public health. Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and a major cause of otitis media, septicemia, and meningitis (1, 2). S. pneumoniae is responsible for ∼1.2 million deaths per year worldwide, with young children and immunocompromised patients at particular risk (3). Neisseria meningitidis causes epidemic bacterial meningitis and septicemia, with high mortality in children and young adults (4). The impact of meningococcal disease on human health is defined by both the risk and the severity of invasive meningococcal infections, with unacceptably high mortality rates, ranging from 10% in patients under optimal clinical therapy with the latest generation of antibiotics to up to 40% in patients with untreated septicemia. Almost one-third of those who survive invasive infections are left with long-term disabilities and long-term morbidity. Globally, the World Health Organization estimates that ∼1.2 million cases of invasive meningococcal infections occur annually, leading to more than 135,000 fatalities (5).Vaccination programs have reduced the rates of infection in developed countries, but neonates and elderly adults remain especially vulnerable (6, 7). The efficacy of vaccination is further limited by the emergence of new strains of S. pneumoniae and N. meningitidis.The complement system plays a major role in the host resistance to both pathogens (8–13). Complement is activated via three routes: the classical pathway, the lectin pathway, and the alternative pathway. Activation of the classical and lectin pathways is mediated by specific recognition molecules. Binding of C1q to the bacterial surface or the Fc region of antibody initiates the classical pathway. The lectin pathway is initiated by carbohydrate recognition molecules, including mannan-binding lectin, ficolins, and collectin 11, which bind directly to bacterial polysaccharides. Activation of the classical or lectin pathway leads to the formation of a C3 convertase (C4b2a), which splits C3 into the biologically active fragments, C3b and C3a. C3b can bind covalently to an activating surface, and hundreds of molecules of C3b can be deposited in close proximity to the C3 convertase complex. Accumulation of C3b close to C4b2a forms the classical pathway C5 convertase C4b2a(3b)n, in which C4b and C3b form a binding site for C5, orienting it for cleavage by C2a (14, 15).The mechanisms initiating the alternative pathway are less well understood. It is widely accepted that the alternative pathway maintains a continuous state of low-rate activation, which is held in check by potent negative regulators of activation on nonactivating surfaces, such as the surface of host cells. Turnover of the alternative pathway is initiated either by the provision of C3b via the classical pathway, the lectin pathway, or complement-independent proteolysis of C3 or by the spontaneous hydrolysis of C3 to form C3(H2O). C3b or C3(H2O) bind factor B to form either the C3bB or C3(H2O)B zymogen complex. In this complex, factor B is cleaved by factor D, releasing a Ba fragment. The activated C3bBb or C3(H2O)Bb fragments are themselves C3 convertases, which in turn cleave more C3 into C3a and C3b. Unchecked, the accumulation of C3b rapidly leads to the formation of more alternative pathway convertase complexes, resulting in a physiologically critical positive feedback mechanism—the amplification loop of complement activation (16). The alternative pathway thus amplifies complement activation initiated by any of the three pathways, making it an attractive target for therapeutic intervention designed to modulate complement-mediated immunity and/or inflammatory processes (17).Deposition of C3b and iC3b on the bacterial surface is a key step in the immune response against S. pneumoniae, because complement-mediated opsonisation is essential for clearance of S. pneumoniae through phagocytosis (8). Lysis of bacteria, owing to formation of the membrane attack complex complex, is the critically important biological activity of complement in the defense against N. meningitidis (10). Inherited or acquired deficiencies of the alternative pathway are associated with a high risk of recurrent bacterial infection. Factor B deficiencies significantly increase the risk of S. pneumoniae and Pseudomonas aeruginosa infection (9, 18). In a mouse model of properdin deficiency, the severity of polymicrobial peritonitis was significantly greater in deficient mice compared with their WT littermates (19). Properdin deficiency in humans has been associated with a high risk of meningococcal infections, especially with unusual infective serotypes, such as W-135 and Y (10, 20, 21). In addition, opsonophagocytosis of S. pneumoniae was found to be severely compromised in properdin-deficient sera, and reconstitution of properdin-deficient sera with purified properdin restored the opsonic activity and killing of S. pneumoniae by polymorphonuclear leukocytes (22, 23).Properdin is the only known positive physiological regulator of complement activation. It stabilizes and extends the half-life of the surface-bound C3 convertase C3bBb, and inhibits its degradation by factor I (24–26). In their pioneering 1954 work, Pillemer et al. (26) first described properdin as a serum protein that mediates complement activation and antimicrobial activity in absence of antibodies.Properdin is present in serum at a concentration of ∼5–15 μg/mL (27). Unlike most other complement components, properdin is not synthesized in the liver but rather is expressed by other cells, including monocytes, T cells, mast cells, and granulocytes (19, 28–30). Properdin monomers can assemble into dimers (P2), trimers (P3), and tetramers (P4), formed by head-to-tail association of monomers (each ∼53 kDa) (31, 32). Properdin aggregates, so-called “activated” properdin (Pn), are considered artificial higher-order oligomers formed during the purification of properdin from plasma or during subsequent freeze–thaw cycles (33). The functional activity of properdin increases with the size of the polymers formed (34). By increasing the half-life of the alternative pathway C3 convertase, properdin antagonizes the functional activity of complement factor H, an abundantly expressed plasma component, which promotes inactivation of the alternative pathway C3 convertase and of all C5 convertases of complement by accelerating the decay of these enzyme complexes through binding to complex-bound C3b and by serving as a cofactor in the factor I-mediated conversion of C3b to its inactive form, termed iC3b (35). Interestingly, the two pathogens used in this study were previously shown to express distinct microbial surface components that sequester factor H from host plasma, leading to resistance to the complement-mediated immune clearance of these pathogens (36, 37).In the present study, we addressed the role of the alternative pathway and the effect of administration of recombinant properdin as a tool for boosting alternative pathway activity to augment the immune response against S. pneumoniae or N. meningitidis. 相似文献
57.
Congenital diaphragmatic hernia: new models,new ideas 总被引:1,自引:0,他引:1
A. E. Brandsma R. Tenbrinck H. Ijsselstijn E. C. Scheffers J. L. J. Gaillard D. Kluth A. A. W. ten Have-Opbroek B. Lachmann D. Tibboel 《Pediatric surgery international》1995,10(1):10-15
An animal model for congenital diaphragmatic hernia following interference with the development of the primary lung bud by 2,4-dinitro-p-diphenylether (nitrofen) is described. It has been used for pathogenetic studies to evaluate the presence of pulmonary hypoplasia and a closing defect of the diaphragm. Functional studies revealed abnormal surfactant levels and differences in pressure/volume curves following birth and during artificial ventilation for 6 h together with a disturbed antioxidant enzyme response. This animal model opens up new ways of studying the effects of prenatal hormonal modulation (corticosteroids, thyrotrophin-releasing hormone) on lung development as a novel therapeutic modality. 相似文献
58.
David RH Christie Kenneth W Tiver 《Journal of Medical Imaging and Radiation Oncology》1996,40(3):331-333
Five patients who received radiotherapy (RT) for 7 melanotic freckles (MF, also known as Hutchinson's freckles, lentigo maligna) were reviewed 8 to 37 months after their treatment by RT. Local control and a favourable cosmetic result occurred in all patients. Treatment toxicity was minimal. Few reports about the use of RT for MF exist. Many other treatments including observation alone have been associated with high rates of recurrence, and in some cases conversion to invasive melanoma has occurred. RT appears to be a safe and effective treatment for this condition, providing that doses equivalent to 44 Gy in 11 fractions or more are given. 相似文献
59.
D Lachmann 《P?diatrie und P?dologie》1987,22(3):293-303
The incidence of EPEC infections has decreased dramatically in industrialized countries since the 1960s, 1970s, but EPEC remains an important of acute gastroenteritis in developing countries. 相似文献
60.
Lambert-Eaton myasthenic syndrome (LEMS) is a type of paraneoplastic syndrome that may initially manifest with weakness and gait abnormalities. These symptoms may precede the diagnosis of malignancy by months or years, and morbidity and mortality may be significantly affected by early detection of the malignancy. A case report and review of the diagnosis, management, and treatment of these syndromes are presented, with particular emphasis on the rehabilitation management of these patients, often overlooked in medical treatment. 相似文献